NYSEAM:ARMPBiotechs
A Look at Armata Pharmaceuticals’s Valuation After Positive Phase 2a Bacteriophage Trial Results (ARMP)
Armata Pharmaceuticals (ARMP) just reported encouraging Phase 2a trial results for its experimental IV bacteriophage therapy, AP-SA02, targeting complicated Staphylococcus aureus bacteremia. The data was revealed during a presentation at IDWeek 2025.
See our latest analysis for Armata Pharmaceuticals.
News of Armata’s clinical breakthrough sent its share price surging 103% in a single day, fueling a remarkable 261% gain for investors year-to-date. Recent momentum has reversed previous years...